At Centauri we seek to tackle life-threatening infectious diseases in the most vulnerable patients.
Our science
Centauri Therapeutics is an immunotherapy company focused on infectious diseases. All projects harness a powerful and clinically validated immune mechanism which redirects naturally existing antibodies to treat life-threatening diseases. Centauri holds an exclusive worldwide license to exploit the Alphamer® immunotherapeutics platform within the field of infectious diseases.
7.0m
immunocompromised people in the United States1 https://www.ama-assn.org/delivering-care/public-health/what-tell-immunocompromised-patients-about-covid-19-vaccines
60%
of haematological cancer deaths are infection related2 Zembower, T.R. (2014). Epidemiology of Infections in Cancer Patients. In: Stosor, V., Zembower, T. (eds) Infectious Complications in Cancer Patients. Cancer Treatment and Research, vol 161. Springer, Chamhttps://doi.org/10.1007/978-3-319-04220-6_2
$4.6bn
health care costs in the US to treat six antibiotic resistance threats3 https://www.cdc.gov/drugresistance/solutions-initiative/stories/partnership-estimates-healthcare-cost.html
67,000
deaths annually in Europe and US due to drug-resistant bacterial infections4 https://www.euro.who.int/en/health-topics/disease-prevention/pages/news/news/2022/01/whoecdc-report-antimicrobial-resistance-remains-threat-to-health-in-european-region 5https://www.cdc.gov/media/releases/2019/p1113-antibiotic-resistant.html
Latest News and Articles
